Basal-like breast cancer displays distinct patterns of promoter methylation

Ji Shin Lee, Mary Jo Fackler, Jae Hyuk Lee, Chan Choi, Min Ho Park, Jung Han Yoon, Zhe Zhang, Saraswati Sukumar

Research output: Contribution to journalArticle

Abstract

Recent microarray profiling studies on breast cancer have identified distinct subtypes that are associated with different clinical outcomes. promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of breast cancer. We proposed that immunohistopathologic subtypes of breast cancer are likely to contain distinct promoter methylation patterns. a panel of 10 gene promoters was assessed by quantitative multiplex methylation-specific PCR in 114 invasive ductal carcinomas from Korea representing the three major subtypes [57 luminal, 24 human epidermal growth factor 2 (HER2), and 33 basal-like] based on immunohistochemical findings of estrogen receptor, progesterone receptor, HER2, cytokeratin 5/6, and epidermal growth factor receptor. The median methylation levels of HIN1, RASSF1A and TWIST, and the average methylation ratio were significantly lower in basal-like subtype compared to luminal or HER2 subtypes. In contrast, BRCA1 methylation level was significantly higher in basal-like subtype than in luminal subtype. The methylation status of a panel of four genes (APC1, CDH, BRCA1 and RAR-β) in luminal and HER2 subtypes were dissimilar, where HER2 tumors showed a significantly higher level of methylation compared to luminal tumors. These results suggest that gene methylation in breast cancer can potentially serve as epigenetic biomarkers and may contribute further to current breast cancer classification.

Original languageEnglish (US)
Pages (from-to)1017-1024
Number of pages8
JournalCancer Biology and Therapy
Volume9
Issue number12
DOIs
StatePublished - Jun 15 2010

Fingerprint

Methylation
Breast Neoplasms
Epidermal Growth Factor
Keratin-6
Keratin-5
Genes
Ductal Carcinoma
Progesterone Receptors
Korea
Tumor Suppressor Genes
Epidermal Growth Factor Receptor
Epigenomics
Estrogen Receptors
Neoplasms
Biomarkers
Polymerase Chain Reaction

Keywords

  • Basal-like
  • Breast cancer
  • HER2
  • Luminal
  • Methylation
  • Quantitation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Basal-like breast cancer displays distinct patterns of promoter methylation. / Lee, Ji Shin; Fackler, Mary Jo; Lee, Jae Hyuk; Choi, Chan; Park, Min Ho; Yoon, Jung Han; Zhang, Zhe; Sukumar, Saraswati.

In: Cancer Biology and Therapy, Vol. 9, No. 12, 15.06.2010, p. 1017-1024.

Research output: Contribution to journalArticle

Lee, Ji Shin ; Fackler, Mary Jo ; Lee, Jae Hyuk ; Choi, Chan ; Park, Min Ho ; Yoon, Jung Han ; Zhang, Zhe ; Sukumar, Saraswati. / Basal-like breast cancer displays distinct patterns of promoter methylation. In: Cancer Biology and Therapy. 2010 ; Vol. 9, No. 12. pp. 1017-1024.
@article{fc84133247074275b43a16d0c9346263,
title = "Basal-like breast cancer displays distinct patterns of promoter methylation",
abstract = "Recent microarray profiling studies on breast cancer have identified distinct subtypes that are associated with different clinical outcomes. promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of breast cancer. We proposed that immunohistopathologic subtypes of breast cancer are likely to contain distinct promoter methylation patterns. a panel of 10 gene promoters was assessed by quantitative multiplex methylation-specific PCR in 114 invasive ductal carcinomas from Korea representing the three major subtypes [57 luminal, 24 human epidermal growth factor 2 (HER2), and 33 basal-like] based on immunohistochemical findings of estrogen receptor, progesterone receptor, HER2, cytokeratin 5/6, and epidermal growth factor receptor. The median methylation levels of HIN1, RASSF1A and TWIST, and the average methylation ratio were significantly lower in basal-like subtype compared to luminal or HER2 subtypes. In contrast, BRCA1 methylation level was significantly higher in basal-like subtype than in luminal subtype. The methylation status of a panel of four genes (APC1, CDH, BRCA1 and RAR-β) in luminal and HER2 subtypes were dissimilar, where HER2 tumors showed a significantly higher level of methylation compared to luminal tumors. These results suggest that gene methylation in breast cancer can potentially serve as epigenetic biomarkers and may contribute further to current breast cancer classification.",
keywords = "Basal-like, Breast cancer, HER2, Luminal, Methylation, Quantitation",
author = "Lee, {Ji Shin} and Fackler, {Mary Jo} and Lee, {Jae Hyuk} and Chan Choi and Park, {Min Ho} and Yoon, {Jung Han} and Zhe Zhang and Saraswati Sukumar",
year = "2010",
month = "6",
day = "15",
doi = "10.4161/cbt.9.12.11804",
language = "English (US)",
volume = "9",
pages = "1017--1024",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "12",

}

TY - JOUR

T1 - Basal-like breast cancer displays distinct patterns of promoter methylation

AU - Lee, Ji Shin

AU - Fackler, Mary Jo

AU - Lee, Jae Hyuk

AU - Choi, Chan

AU - Park, Min Ho

AU - Yoon, Jung Han

AU - Zhang, Zhe

AU - Sukumar, Saraswati

PY - 2010/6/15

Y1 - 2010/6/15

N2 - Recent microarray profiling studies on breast cancer have identified distinct subtypes that are associated with different clinical outcomes. promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of breast cancer. We proposed that immunohistopathologic subtypes of breast cancer are likely to contain distinct promoter methylation patterns. a panel of 10 gene promoters was assessed by quantitative multiplex methylation-specific PCR in 114 invasive ductal carcinomas from Korea representing the three major subtypes [57 luminal, 24 human epidermal growth factor 2 (HER2), and 33 basal-like] based on immunohistochemical findings of estrogen receptor, progesterone receptor, HER2, cytokeratin 5/6, and epidermal growth factor receptor. The median methylation levels of HIN1, RASSF1A and TWIST, and the average methylation ratio were significantly lower in basal-like subtype compared to luminal or HER2 subtypes. In contrast, BRCA1 methylation level was significantly higher in basal-like subtype than in luminal subtype. The methylation status of a panel of four genes (APC1, CDH, BRCA1 and RAR-β) in luminal and HER2 subtypes were dissimilar, where HER2 tumors showed a significantly higher level of methylation compared to luminal tumors. These results suggest that gene methylation in breast cancer can potentially serve as epigenetic biomarkers and may contribute further to current breast cancer classification.

AB - Recent microarray profiling studies on breast cancer have identified distinct subtypes that are associated with different clinical outcomes. promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of breast cancer. We proposed that immunohistopathologic subtypes of breast cancer are likely to contain distinct promoter methylation patterns. a panel of 10 gene promoters was assessed by quantitative multiplex methylation-specific PCR in 114 invasive ductal carcinomas from Korea representing the three major subtypes [57 luminal, 24 human epidermal growth factor 2 (HER2), and 33 basal-like] based on immunohistochemical findings of estrogen receptor, progesterone receptor, HER2, cytokeratin 5/6, and epidermal growth factor receptor. The median methylation levels of HIN1, RASSF1A and TWIST, and the average methylation ratio were significantly lower in basal-like subtype compared to luminal or HER2 subtypes. In contrast, BRCA1 methylation level was significantly higher in basal-like subtype than in luminal subtype. The methylation status of a panel of four genes (APC1, CDH, BRCA1 and RAR-β) in luminal and HER2 subtypes were dissimilar, where HER2 tumors showed a significantly higher level of methylation compared to luminal tumors. These results suggest that gene methylation in breast cancer can potentially serve as epigenetic biomarkers and may contribute further to current breast cancer classification.

KW - Basal-like

KW - Breast cancer

KW - HER2

KW - Luminal

KW - Methylation

KW - Quantitation

UR - http://www.scopus.com/inward/record.url?scp=77954406621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954406621&partnerID=8YFLogxK

U2 - 10.4161/cbt.9.12.11804

DO - 10.4161/cbt.9.12.11804

M3 - Article

VL - 9

SP - 1017

EP - 1024

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 12

ER -